Summary
Pooled data from the SECURE and VITAL global phase 3 multicenter trials have demonstrated the effectiveness of isavuconazole in the treatment of invasive aspergillosis in patients with renal insufficiency. Other intravenous triazole antifungals are contraindicated in these patients. Dose adjustment of isavuconazole is not needed.
- invasive aspergillosis
- isavuconazole
- triazole antifungals
- renal dysfunction
- infectious diseases clinical trials
- fungal infections
- © 2015 SAGE Publications
Tools
Isavuconazole Safe, Effective in Treatment of IA in Patients With Renal Insufficiency
Permalink:
